Alps Group (Nasdaq: ALPS) launches patient-derived organoid cancer program
Rhea-AI Filing Summary
Alps Group Inc, a Malaysia-based biotechnology company, is expanding into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun of Axiocell Biotech. The company is launching an internal PDO program focused on personalized cancer treatment and preclinical drug screening.
Alps aims to build Malaysia’s first clinically validated PDO platform, pursue MREC ethics approval and Medical Device Authority registration, and create a national PDO biobank to support pharmaceutical and CRO partners. The program targets major oncology centers in Malaysia, where about 51,650 new cancer cases are recorded annually and most are diagnosed at advanced stages.
Positive
- None.
Negative
- None.
Insights
Alps is positioning itself in precision oncology by adding PDO technology to its existing platform.
Alps Group Inc is entering patient-derived organoid (PDO) technology via a collaboration with Axiocell Biotech’s Dr. Kong Wai Mun. PDOs allow growth of mini-tumors from patient tissue, enabling ex vivo testing of how an individual’s cancer responds to multiple therapies.
The company plans to obtain MREC ethics approval and Medical Device Authority registration, signaling intent to use PDOs in clinical decision support rather than only research. Plans for a national PDO biobank and services for pharmaceutical and CRO partners connect the initiative to potential future commercial testing and drug-screening revenue streams.
Context in the disclosure highlights sizable global markets for organoids and personalized cancer treatment and notes that 64.8% of Malaysian cancer cases are diagnosed at advanced stages. This suggests a clinical need for better treatment selection tools, though actual financial impact for Alps will depend on successful validation, regulatory approvals, and adoption by the six oncology centers initially expressing interest.
Key Figures
Key Terms
patient-derived organoid (PDO) technology medical
precision oncology medical
preclinical drug screening medical
PDO biobank medical
MREC ethics approval regulatory
Medical Device Authority (MDA) regulatory registration regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 001-42915
Alps Group Inc
(Registrant’s Name)
Unit E-18-01 & E-18-02, Level 18, Icon Tower (East)
No. 1, Jalan 1/68F, Jalan Tun Razak
50400 Kuala Lumpur
Wilayah Persekutuan, Malaysia
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information Contained in this Form 6-K Report
Attached hereto as Exhibit 99.1 is a press release dated June 23, 2026 issued by Alps Group Inc (the “Company”), announcing the launch of patient-derived organoid program to advance personalized cancer care in Southeast Asia.
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated June 23, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alps Group Inc | ||
| Date: June 23, 2026 | By: | /s/ Dr. Tham Seng Kong |
| Name: | Dr. Tham Seng Kong | |
| Title: | Chief Executive Officer and Director | |
Exhibit 99.1
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia’s First Clinically Validated PDO Platform
KUALA LUMPUR, Malaysia – June 23, 2026 – Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development.
Under the agreement, Alps is launching an internal PDO program targeting personalized cancer treatment and preclinical drug screening, a fast-growing field in precision oncology. According to Future Market Insights, the global human organoids market was valued at approximately USD 91.8 million in 2026 and is projected to reach USD 349.5 million by 2036, growing at a CAGR of 14.3%. The global personalized cancer treatment market was valued at approximately USD 222.54 billion in 2026 and is projected to reach USD 332.37 billion by 2030, growing at a CAGR of 10.5%.1 Alps aims to develop Malaysia’s first clinically validated PDO platform with a defined regulatory pathway that includes obtaining MREC ethics approval and Medical Device Authority (MDA) regulatory registration to support clinical deployment and commercialization.
PDO technology involves growing three-dimensional “mini-tumors” from a patient’s own cancer tissue, allowing clinicians and researchers to evaluate how individual tumors may respond to different therapies. This approach is designed to improve treatment selection, accelerate drug development, and reduce reliance on animal testing.
Alps plans to establish a national PDO biobank to support preclinical drug screening and licensing services for pharmaceutical and CRO partners, with a long-term goal of positioning Malaysia as a regional hub for PDO-based translational research. The program has identified initial clinical interest across six major oncology centers in Malaysia. According to GLOBOCAN 2022, Malaysia records approximately 51,650 new cancer cases per year.2 The Malaysia National Cancer Registry Report further notes that 64.8% of cases are diagnosed at advanced stages.3
“PDO technology is a natural extension of Alps’ integrated platform, bringing together our existing genomic, manufacturing, and clinical capabilities to deliver truly personalized oncology care,” said Dr. Tham Seng Kong, Executive Director and Group Chief Executive Officer of Alps Group Inc. “By predicting how a patient’s tumor responds to treatment before therapy begins, PDO technology represents a meaningful step toward making advanced cancer care accessible and affordable for patients across Southeast Asia.”
1 Organoids market: Future Market Insights, Organoids Market Report (2026–2036). Global personalized cancer treatment market: The Business Research Company, Personalized Cancer Treatment Global Market Report 2026.
2 International Agency for Research on Cancer. Malaysia: GLOBOCAN 2022 Fact Sheet. World Health Organization.
3 National Cancer Registry Department, Institut Kanser Negara. Malaysia National Cancer Registry Report 2017–2021, p. 26. Ministry of Health Malaysia, 2025.
Kong Wai Mun, PhD, Executive Director of Axiocell Biotech, commented, “PDO technology holds significant promise in bridging the gap between laboratory research and clinical application. By enabling clinicians and researchers to evaluate how a patient’s tumor may respond to treatment before therapy is administered, PDO platforms have the potential to support more personalized approaches to cancer care. PDOs also serve as a powerful preclinical platform for translational research and can function as a form of early clinical trial simulation. This program represents an important step for precision oncology research in Malaysia, one that builds on world-class clinical expertise already present in the country while creating the infrastructure needed to translate that expertise into better outcomes for patients.”
To be added to the Alps Group Inc email distribution list, please email Alps@kcsa.com with ALPS in the subject line.
About Alps Group Inc
Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development, with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.
Forward-Looking Statements
Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
Investor Relations Contact
Philip Carlson
KCSA Strategic Communications
Phone: 212.896.1233
Email: Alps@kcsa.com